Thymosin α-1 is an endogenous immunomodulatory peptide originally isolated from thymic tissue as the active component responsible for restoring immune function in thymectomized animals. Comprising the N-terminal 28 residues of prothymosin α, Tα1 enhances both innate and adaptive immune responses: it promotes T-cell differentiation, activates natural killer and dendritic cells, and stimulates Toll-like receptors on myeloid and plasmacytoid dendritic cells, leading to up-regulation of cytokine-signalling pathways. Studies show that Tα1's pleiotropic actions include boosting pro-inflammatory cytokine release and modulating dendritic cell maturation. Because of these properties, the peptide has been examined as an adjuvant to chemotherapy or immunotherapy, where it may mitigate treatment-induced immunosuppression and enhance effector-cell infiltration. Researchers also investigate its role in antiviral and vaccine contexts, evaluating how Tα1 engages Toll-like receptors and downstream signalling to bolster T-cell, B-cell and natural killer cell responses. This product is provided exclusively for laboratory study of immune-modulation pathways and is not intended for human or veterinary consumption.